EXAGEN INC.

The company is a medical technology company that designs, develops, and sells innovative testing products under its AVISE® brand. These products are used for the diagnosis, prognosis, and monitoring of complex rheumatic, autoimmune, and autoimmune-related diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's tests are utilized in various clinical settings to aid in decision-making for autoimmune diseases, aiming to improve patient outcomes. The flagship product, AVISE® CTD, was commercially launched in 2012. AVISE® CTD helps differentiate diagnoses for patients with symptoms of various connective tissue diseases (CTDs) and related conditions with overlapping symptoms. This product provides unique biomarkers to assist clinicians in diagnosing CTDs. In 2025, eight new biomarkers were added to the AVISE® CTD panel to enhance its clinical utility in diagnosing SLE and RA. Revenue from AVISE® CTD accounted for 91% of the company's total revenue for both the years ended December 31, 2025, and 2024. Starting in late 2022, the company strengthened its senior leadership team with new members in key roles, including Chief Executive Officer, Chief Financial Officer, Chief Scientific Officer, Vice President of Sales, Vice President of Commercial Strategy, and Medical and Laboratory Director.